Rosati G - Search Results

1

Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial.

Basile D, Rosati G, Bergamo F, Garattini SK, Banzi M, Zampino M, Bozzarelli S, Marchetti P, Galli F, Galli F, Longarini R, Zaniboni A, Ferrari D, De Placido S, Frassineti LG, Nicolini M, Cinieri S, Priscindiaro M, Ziranu P, Caccialanza R, Pastorino A, Mosconi S, Aprile G. Basile D, et al. Among authors: rosati g. Clin Colorectal Cancer. 2023 Jun;22(2):190-198. doi: 10.1016/j.clcc.2023.01.004. Epub 2023 Feb 5. Clin Colorectal Cancer. 2023. PMID: 36935327 Clinical Trial.

2

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Calabrò F, et al. Among authors: rosati g. Cancer. 2009 Jun 15;115(12):2652-9. doi: 10.1002/cncr.24313. Cancer. 2009. PMID: 19396817 Free article. Clinical Trial.

3

Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.

Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Rosati G, et al. Invest New Drugs. 2012 Oct;30(5):1978-83. doi: 10.1007/s10637-011-9721-6. Epub 2011 Jul 19. Invest New Drugs. 2012. PMID: 21769636 Clinical Trial.

4

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. Rosati G, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):257-64. doi: 10.1007/s00280-012-2004-x. Epub 2012 Oct 26. Cancer Chemother Pharmacol. 2013. PMID: 23100174 Clinical Trial.

5

Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study.

Lutrino SE, Bergamo F, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Llimpe FR, Pisa FE, Lonardi S, Loupakis F, Fasola G, Aprile G. Lutrino SE, et al. Among authors: rosati g. Anticancer Res. 2015 Apr;35(4):2391-9. Anticancer Res. 2015. PMID: 25862905 Clinical Trial.

6

A perspective on the current treatment strategies for locally advanced rectal cancer.

Avallone A, Aloj L, Aprile G, Rosati G, Budillon A. Avallone A, et al. Among authors: rosati g. Int J Biochem Cell Biol. 2015 Aug;65:192-6. doi: 10.1016/j.biocel.2015.06.002. Epub 2015 Jun 6. Int J Biochem Cell Biol. 2015. PMID: 26055517 Review.

7

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.

Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, Casagrande M, Ongaro E, Berretta M, Avallone A, Rosati G, Giuliani F, Fasola G. Aprile G, et al. Among authors: rosati g. Oncotarget. 2015 Oct 6;6(30):28716-30. doi: 10.18632/oncotarget.4747. Oncotarget. 2015. PMID: 26308250 Free PMC article. Review.

8

A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer.

Rosati G, Aprile G, Cardellino GG, Avallone A. Rosati G, et al. J Geriatr Oncol. 2016 Mar;7(2):134-41. doi: 10.1016/j.jgo.2016.01.006. Epub 2016 Feb 18. J Geriatr Oncol. 2016. PMID: 26897044 Review.

9

Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.

Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrari D, Lo Re G, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Frassoldati A, Bilancia D, Campanella GA, Signorelli C, Racca P, Benincasa E, Stroppolo ME, Di Costanzo F. Pinto C, et al. Among authors: rosati g. Cancer Med. 2016 Nov;5(11):3272-3281. doi: 10.1002/cam4.888. Epub 2016 Oct 17. Cancer Med. 2016. PMID: 27748041 Free PMC article.

10

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G. Fanotto V, et al. Among authors: rosati g. Gastric Cancer. 2017 Sep;20(5):825-833. doi: 10.1007/s10120-016-0681-6. Epub 2016 Dec 27. Gastric Cancer. 2017. PMID: 28028664

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

449 results

Search Page